Compare ESP & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESP | MSLE |
|---|---|---|
| Founded | 1928 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 154.6M |
| IPO Year | 1995 | N/A |
| Metric | ESP | MSLE |
|---|---|---|
| Price | $60.70 | $9.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $64.00 | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 63.2K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $22.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.00 | $5.44 |
| 52 Week High | $74.77 | $13.39 |
| Indicator | ESP | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 75.47 |
| Support Level | $52.70 | $6.71 |
| Resistance Level | $61.58 | $13.39 |
| Average True Range (ATR) | 3.67 | 0.68 |
| MACD | -0.50 | 0.35 |
| Stochastic Oscillator | 11.59 | 91.12 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.